AstraZeneca was among the first seven companies globally to have its net zero targets verified by the Science-Based Targets initiative’s corporate net zero standard. Investment in green gas, reforestation and the associated use of AI mark the company out as a thought leader in sustainability initiatives. In this context, COP28’s renewed focus on ‘climate+health’ is well timed.
The adoption of corporate climate change efforts and initiatives continues to expand, including by health care companies, although they are frequently cast as being slow out of the blocks to modernize and embrace change.
Not so the health care players with whom In Vivo has spoken over the past 18 months for its rolling...
Launching In Vivo’s oncology therapeutic review series, this first instalment provides a data-led primer on the global cancer landscape. Future instalments will explore market dynamics, pipeline evolution and the innovations set to define oncology therapeutics through 2032.
Launching In Vivo’s oncology therapeutic review series, this first instalment provides a data-led primer on the global cancer landscape. Future instalments will explore market dynamics, pipeline evolution and the innovations set to define oncology therapeutics through 2032.
Launching In Vivo’s oncology therapeutic review series, this first instalment provides a data-led primer on the global cancer landscape. Future instalments will explore market dynamics, pipeline evolution and the innovations set to define oncology therapeutics through 2032.
